A Study to Observe the Onset of Immune-related Adverse Reactions in Patients With Non-surgical or Renal Cell Carcinoma (RCC) That Has Spread
NCT03663946 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 81
Last updated 2022-02-25
Summary
Patients with non-surgical or renal cell carcinoma that has spread who are starting treatment for the first time with Yervoy and Opdivo in the real world
Conditions
Interventions
- OTHER
-
Non-Interventional
Non-Interventional
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Bristol-Myers Squibb · Bristol-Myers Squibb
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-09-18
- Primary Completion
- 2020-05-30
- Completion
- 2020-05-30
Countries
- Japan
Study Locations
More Related Trials
-
Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)
NCT03203473 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)
NCT01354431 ·Status: COMPLETED ·Phase: PHASE2
-
Non-Interventional Study (NIS) of Nivolumab With or Without Ipilimumab in Participants With Advanced Kidney Cancer
NCT03455452 ·Status: ACTIVE_NOT_RECRUITING
-
Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and Nivolumab
NCT03126331 ·Status: COMPLETED ·Phase: PHASE2
-
Nivolumab and Ipilimumab in T1aN0M0 Renal Cell Carcinoma Patients Ineligible for Surgical Treatment.
NCT04134182 ·Status: UNKNOWN ·Phase: PHASE2
-
An Observational Chart Review Study To Describe The Real-World Outcomes And Use Of Avelumab In Combination With Axitinib For Treatment Of Patients With aRCC In The UK
NCT05394493 ·Status: COMPLETED
-
A Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in India
NCT04513522 ·Status: COMPLETED ·Phase: PHASE4
-
Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC
NCT06860386 ·Status: SUSPENDED ·Phase: PHASE2
-
Research Study for Patients With Metastatic Renal Cell Carcinoma
NCT00110344 ·Status: TERMINATED ·Phase: PHASE2
-
Optimization of Management for Sporadic Bilateral Renal Cell Carcinoma
NCT06369519 ·Status: COMPLETED
-
An Observational Study to Evaluate the Efficacy and Safety of Avelumab + Axitinib Combination in Participants With aRCC (AVION)
NCT04941768 ·Status: COMPLETED
-
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
NCT03291028 ·Status: ACTIVE_NOT_RECRUITING
-
Retrospective Study on the Safety of Nivolumab in Patients With mRCC and Renal Failure
NCT07117409 ·Status: TERMINATED
-
A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
NCT03141177 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma
NCT03297593 ·Status: COMPLETED ·Phase: PHASE2
-
Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer
NCT01239342 ·Status: TERMINATED ·Phase: PHASE2
-
An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma
NCT02596035 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of the Effectiveness of Cabozantinib in Combination With Nivolumab as First-line Treatment of Advanced Renal Cell Carcinoma (aRCC) in Adults
NCT05361434 ·Status: ACTIVE_NOT_RECRUITING
-
Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic Regimen
NCT03013335 ·Status: COMPLETED ·Phase: PHASE2
-
Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)
NCT01472081 ·Status: COMPLETED ·Phase: PHASE1
-
Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
NCT05678673 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma
NCT04088500 ·Status: TERMINATED ·Phase: PHASE2
-
A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With Metastatic RCC
NCT01673386 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma
NCT03635892 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2)
NCT01266837 ·Status: COMPLETED ·Phase: PHASE4